NASDAQ: BTMDBiote Corp Stock
$1.12-0.01 (-0.88%)
Updated Nov 3, 2026
BTMD Price
$1.12
Fair Value Price
N/A
Market Cap
$40.24M
52 Week Low
$1.00
52 Week High
$2.98
P/E
7x
P/B
-0.61x
P/S
0.3x
PEG
0.13x
Dividend Yield
N/A
Revenue
$183.53M
Earnings
$5.86M
Gross Margin
68.6%
Operating Margin
10.02%
Profit Margin
3.2%
Debt to Equity
-2.43
Operating Cash Flow
$24M
Beta
0.6
Next Earnings
Nov 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BTMD Overview
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BTMD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
BTMD
Ranked#31 of 40
Ranked#31 of 40
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.85 | A | |
| $266.69 | A | |
| $533.65 | A |
Be the first to know about important BTMD news, forecast changes, insider trades & much more!
BTMD News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BTMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BTMD ($1.12) is trading below its intrinsic value of $3.27, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BTMD is good value based on its earnings relative to its share price (7x), compared to the US market average (44.51x)
P/E vs Market Valuation
BTMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BTMD due diligence checks available for Premium users.
Valuation
BTMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
7x
Industry
16.83x
Market
44.51x
BTMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BTMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
BTMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.61x
Industry
5.81x
BTMD price to earnings growth (PEG)
For valuing profitable companies with growth potential
BTMD is good value based... subscribe to Premium to read more.
PEG Value Valuation
BTMD's financial health
Profit margin
Revenue
$44.2M
Net Income
-$6.6M
Profit Margin
-14.8%
BTMD's Earnings (EBIT) of $18.39M... subscribe to Premium to read more.
Interest Coverage Financials
BTMD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$101.7M
Liabilities
$159.9M
Debt to equity
-2.43
BTMD's short-term assets ($43.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BTMD's long-term liabilities ($129.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BTMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BTMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$2.6M
Financing
$9.6M
BTMD's operating cash flow ($24.37M)... subscribe to Premium to read more.
Debt Coverage Financials
BTMD vs Medical Care Facility Stocks
Biote Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.